Maropitant Production Cost Reports

The report provides detailed analysis essential for establishing a maropitant production plant. It encompasses all critical aspects necessary for maropitant production, including the cost of maropitant production, maropitant plant cost, maropitant production costs, and the overall maropitant production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a maropitant production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Maropitant Market Analysis: Demand and Supply Analysis, and Sourcing

Maropitant is a veterinary antiemetic used to prevent and treat vomiting in dogs and cats in clinics, hospitals, shelters, and homes. It blocks the neurokinin-1 receptor in the brain's vomiting center, so substance P cannot trigger the vomiting reflex. Pfizer discovered it, developed it, and patented its process, and Zoetis now sells it as Cerenia. The FDA approved Cerenia tablets for dogs in January 2007, and the injection covers both dogs and cats. It is one of the most widely used drugs in small-animal practice, emergency care, surgery, and oncology. Vets give it before surgery, during gastroenteritis, before car travel, and alongside chemotherapy.

Demand for maropitant follows the companion animal market. Pet ownership, vet visit numbers, insurance coverage, and spending per pet keep rising in the US, Europe, Japan, and parts of China. Cerenia held the market alone for many years. That changed when ZyVet Animal Health won the first FDA approval for generic maropitant citrate tablets in 16, 24, 60, and 160 mg strengths. Dechra followed with Emeprev, the first FDA-approved bioequivalent injectable, and its Prevomax brand serves Europe. Generic entry is now lowering prices, widening use in clinics, and pushing buying groups, distributors, and  corporate practices to switch.

API supply has moved from the originator's network to a mix of Chinese and European producers. Apino Pharma and Sichuan Qingmu Pharmaceutical in China and Procos in Italy list maropitant citrate as producers. Distributors in Denmark, the US, and China also offer the API with US DMF or veterinary master file support. A maropitant demand and supply analysis has to weigh rising pet care spending, falling prices after generic entry, and the narrow base of qualified API makers.

Summary of the Product, Grades, and Uses

Maropitant has the molecular formula C32H40N2O, a molar mass of 468.67 g/mol, and the CAS number 147116-67-4. The commercial salt is maropitant citrate monohydrate, C32H40N2O·C6H8O7·H2O, with a molar mass of 678.81 g/mol and CAS 359875-09-5. Its chemical name is 2-benzhydryl-N-[5-tert-butyl-2-methoxybenzyl]quinuclidin-3-amine, in the 2S,3S form. The molecule has two stereocenters on the quinuclidine ring, both of which must be S. Physically, the citrate is a white to off-white, crystalline, slightly bitter powder. It is soluble in alcohol and practically insoluble in water. Form I is the stable crystal form used in finished products. Other forms and solvates must stay below detection.

Maropitant is sold mainly as GMP-grade citrate monohydrate for veterinary dosage forms. Buyers test assay by HPLC, related substances, the R, R-enantiomer and other stereoisomers by chiral HPLC, water content, citrate content, residual solvents, palladium and platinum, and crystal form by XRPD. Particle size matters for tablet blending, content uniformity, compression, and dissolution. Reference standards, impurity standards, and stereoisomer standards are sold in milligram lots to QC, CRO, and research labs. Research grade is offered by catalog suppliers for NK1 receptor work.

Finished forms are tablets and injections. Cerenia and generic tablets come in 16, 24, 60, and 160 mg strengths. Cerenia injection uses a cyclodextrin solution at 10 mg/mL. Dechra's Emeprev injection is also 10 mg/mL, preserved with benzyl alcohol, and does not need refrigeration. Products carry warnings on skin and eye contact for owners, vet nurses, pharmacists, and anyone handling broken tablets.

Main End-Uses of Maropitant

Acute vomiting in dogs is the main use of maropitant. Vets use it to treat vomiting caused by gastroenteritis, dietary indiscretion, pancreatitis, kidney disease, liver disease, parvovirus, and other conditions. Tablets are usually given at 2 mg/kg once a day for up to five days. The injection works quickly and is used in general veterinary clinics, emergency hospitals, referral centers, and animal shelters. Many vets also use maropitant before anesthesia to help prevent vomiting caused by opioids. This routine use creates steady demand in veterinary surgical practices.

Motion sickness is the second use of maropitant in dogs, and it brings in owners, groomers, boarding kennels, and pet travel firms. Owners give a higher tablet dose of 8 mg/kg before car trips, for up to two days. Pet travel, boarding, relocation, holidays, and long road trips keep this use steady. Breeders, show handlers, and pet transport firms also buy it through vets.

Cats, cancer treatment, and supportive care also add to maropitant demand. The injection is used to treat vomiting in cats aged four months and older. Oncologists use maropitant to control nausea during chemotherapy with medicines such as cisplatin, doxorubicin, and cyclophosphamide. Some vets also use it off-label for pain relief, reducing inflammation, and treating coughing linked to airway diseases. Research laboratories buy small quantities for studies on NK1 receptors, pain, coughing, and animal behavior.

Maropitant Market Risks

Maropitant faces several market risks as the original single-brand drug now faces generic competition. Generic tablets and a bioequivalent injection compete with Cerenia, putting pressure on prices. Clinics may switch to lower-cost products, while buying groups, corporate veterinary chains, online pharmacies, and distributors ask for higher discounts. Veterinary demand is much smaller than demand for human medicines, so only a few API manufacturers may find it worthwhile to file for the product. A supply problem at one approved API supplier could affect several finished-dose manufacturers at the same time. Most buyers keep only a few months of stock. New antiemetic medicines, long-acting formulations, transdermal products, and combination treatments could also reduce maropitant demand over time.

Maropitant production has several risks because the molecule has two stereocenters and a complex quinuclidine structure. The required 2S,3S form must be separated correctly and maintained through all later production steps. Grignard reactions need dry solvents, inert gas, slow addition, and careful temperature control. The two hydrogenation steps require pressure equipment and precious metal catalysts. Any remaining palladium or platinum must be removed to meet quality limits. Salt formation must produce the correct monohydrate crystal form because other forms can affect stability and dissolution. Batches are commonly rejected because of incorrect stereoisomer levels, residual metals, residual solvents, or the wrong crystal form.

Maropitant Production Process and Main Cost Drivers

The maropitant production process runs from 3-quinuclidinone receipt through benzylidene condensation, Grignard addition, tartaric acid resolution, benzylamine reductive amination, debenzylation, aldehyde reductive amination, citrate salt formation, crystallization, drying, and packing.

1. By Quinuclidinone Benzhydrylation, Tartrate Resolution and Reductive Amination: The main inputs are 3-quinuclidinone, benzaldehyde, phenylmagnesium chloride, L-tartaric acid, benzylamine, aluminum isopropoxide, 5-tert-butyl-2-methoxybenzaldehyde, platinum and palladium on carbon, hydrogen, citric acid, and solvents.

Maropitant production starts with 3-quinuclidinone, a bicyclic amine ketone that is also used to make solifenacin, cevimeline, and other quinuclidine medicines. It first reacts with benzaldehyde in an aldol-type reaction to form 2-benzylidene-3-quinuclidinone. Phenylmagnesium chloride is then added to the double bond to produce racemic 2-benzhydryl-3-quinuclidinone, which contains both R and S forms. A Pfizer patent describes separating the required form using L-tartaric acid in ethanol and acetic acid. Under these reaction conditions, the unwanted R-isomer changes into the S-isomer, allowing the S-ketone tartrate to form in 85% to 90% yield. The salt is then separated to obtain the ketone. It reacts with benzylamine and aluminum isopropoxide in THF to form an imine. Platinum on carbon and hydrogen at about 75 psi then reduce the imine to produce the cis 2S,3S N-benzyl amine with more than 99% enantiomeric excess.

The benzyl group is then removed by hydrogenation over palladium on carbon in isopropanol, at about 75 to 80 degree Celsius and 50 psig. Without isolating the free amine, 5-tert-butyl-2-methoxybenzaldehyde is added to the same pot. Further hydrogenation for about 3.5 hours forms maropitant base. Caustic workup, phase separation, extraction, and crystallization from isopropanol give clean free base. The base then reacts with about 1.1 equivalents of anhydrous citric acid in acetone and water. Adding tert-butyl methyl ether precipitates maropitant citrate monohydrate in Form I. Pfizer's improved sequence lifted overall yield from about 68% to about 76%. It also cut isolations, solvent swaps, and handling time. Resolution yield, catalyst use, and final crystallization set most of the conversion cost.

Main Factors Affecting Maropitant Production Cost

Maropitant production cost mainly depends on the yield of each step, the cost of specialty intermediates, and the use of precious metal catalysts. The process has six or more chemical steps, including two hydrogenation steps, one resolution step, and one salt formation step before the final citrate is made. Losses at each stage add up, so the yield of each step affects the amount and cost of raw materials needed for the earlier steps. The dynamic kinetic resolution is useful because it converts the unwanted ketone form into the required form instead of losing half of the starting material. 5-tert-butyl-2-methoxybenzaldehyde is a specialty raw material with only a few suppliers. Platinum and palladium catalysts are expensive, so recovering, reusing, and refining these metals can have a major effect on production cost.

Production scale and quality requirements also affect the cost. Veterinary demand is small compared with human medicines, so maropitant is usually made in short campaigns, often once or twice a year, using shared reactors, filters, and dryers. Fixed costs for GMP staff, quality control, validation, and regulatory documents make up a large part of the cost per kilogram. Quality testing includes HPLC for assay and impurities, chiral HPLC for stereoisomers, GC for residual solvents, ICP for metals, Karl Fischer testing for water, and XRPD for the crystal form. Reworking batches that fail because of stereoisomer levels, metals, solvents, or crystal form can take time and add high costs. Recovering solvents such as THF, isopropanol, acetone, and MTBE helps reduce both production costs and waste.

Raw Materials for Maropitant Production Plant and its Procurement

Raw material sourcing for maropitant centers on 3-quinuclidinone and 5-tert-butyl-2-methoxybenzaldehyde. 3-Quinuclidinone, usually sold as its hydrochloride, comes from Chinese and Indian fine chemical makers that also serve quinuclidine drugs such as solifenacin and cevimeline. Benzaldehyde, benzylamine, chlorobenzene, and citric acid are commodity chemicals. Phenylmagnesium chloride is made from chlorobenzene and magnesium in THF, or bought in solution. L-tartaric acid comes from wine industry by-products in Italy, Spain, France, and Argentina. Platinum and palladium catalysts come from refiners such as Johnson Matthey, BASF, Evonik, and Heraeus. Citric acid, aluminum isopropoxide, and process solvents complete the list.

Raw material quality directly affects the impurity levels in the final maropitant API. 3-Quinuclidinone must have low moisture and low levels of related bases. The substituted benzaldehyde must contain very low levels of positional isomers because they can form similar compounds that are difficult to remove later. THF used in the Grignard reaction must be dry and free from peroxides. Supply contracts for maropitant raw materials usually set limits for assay, isomer content, water, and residual solvents. Each incoming raw material batch is sampled, tested, recorded, and kept in quarantine until QC approval. Supplier records include audit reports, change control information, nitrosamine risk statements, and certificates of analysis. Having two approved suppliers for 3-quinuclidinone and the substituted benzaldehyde helps prevent supply problems and keeps production campaigns running.

Sustainability and Regulatory Requirements

Maropitant production has environmental and safety concerns related to Grignard reagents, hydrogen, and organic solvents. Grignard reactions are carried out under nitrogen with controlled addition because magnesium reagents can react strongly with water and air. Hydrogenation is done in pressure-rated, explosion-proof areas with hydrogen detectors, nitrogen purging, rupture discs, and flame arresters. Used palladium and platinum catalysts are kept wet, washed, packed in drums, and sent for metal recovery. Wastewater can contain magnesium salts, aluminum salts, tartrate, and small amounts of solvents. It needs neutralization, solvent removal, and biological treatment before discharge. Recovering solvents such as THF, isopropanol, acetone, and MTBE helps reduce waste and production costs.

Regulatory requirements for maropitant are based on its use as a veterinary medicine for dogs and cats. In the US, the FDA Center for Veterinary Medicine approved Cerenia through a new animal drug application. Generic products use abbreviated applications that show bioequivalence or sameness. API manufacturers support these applications through US DMFs or veterinary master files. In Europe, Cerenia and generic products such as Prevomax are approved under the EU veterinary medicines regulation. API plants follow GMP requirements for veterinary active ingredients, while impurities and residual solvents are controlled under VICH and ICH guidelines. Since maropitant is used in dogs and cats rather than food-producing animals, residue limits do not apply. Product labels still need to include safety, storage, disposal, and handling information because the API can irritate the skin and eyes.

CAPEX and OPEX for a Maropitant Production Plant

The maropitant plant setup cost begins with glass-lined and stainless reactors in the 500 to 4,000 L range for condensation, Grignard addition, resolution, and salt formation. A Grignard reactor needs dry nitrogen, controlled dosing, and strong cooling. A pressure-rated hydrogenator with catalyst filtration, hydrogen supply, nitrogen purge, and gas detection serves both reductive amination steps. Downstream sit crystallizers, a Nutsche filter dryer or centrifuge, a vacuum dryer, and a mill. Utilities cover chilled brine, steam, nitrogen, purified water, and solvent recovery. On the QC side, the lab holds HPLC, chiral HPLC, GC, ICP-MS, Karl Fischer, and XRPD.

Maropitant operating cost is led by intermediates, catalysts, and labor. 3-Quinuclidinone, the substituted benzaldehyde, phenylmagnesium chloride, and catalyst losses lead the variable side. Solvents, hydrogen, nitrogen, utilities, and waste treatment come next. Fixed costs cover GMP staff, validation, audits, DMF and veterinary file upkeep, depreciation, and maintenance on the hydrogenator. Plants that run maropitant beside other veterinary or human small-volume APIs reach a much lower cost per kilogram.

Plant Location and Investment Factors

A suitable maropitant plant should be in an API manufacturing area that already handles Grignard reactions and hydrogenation. In China, Sichuan, Zhejiang, Jiangsu, and Shandong have fine chemical and API manufacturers with experience in veterinary medicines. Northern Italy has European plants with FDA and EU inspection records, including Procos near Novara. API clusters around Hyderabad and Gujarat in India offer lower-cost multipurpose production. The site needs permits for high-pressure hydrogen handling, solvent recovery, and wastewater treatment. It also needs trained analysts who can test chiral purity and crystal forms.

For a maropitant project, the first investment decision is the production scale. Global veterinary demand is modest, so a separate plant is usually not practical. Most manufacturers make maropitant in batches using shared equipment that is also used for other chiral, amine, and quinuclidine APIs. The second decision is whether to make the main intermediates in-house or buy them. These include quinuclidinone, substituted benzaldehyde, the Grignard reagent, and catalysts. Making 3-quinuclidinone or substituted benzaldehyde in-house can give better control over supply but adds more production steps and safety risks. The third decision is the target market. A US DMF or veterinary master file can help supply generic manufacturers in the US, while EU GMP approval can support products such as Prevomax in Europe.

Major Maropitant Producing Regions

China is the main source of generic maropitant citrate API. Apino Pharma and Sichuan Qingmu Pharmaceutical list it as producers, and Chinese distributors such as Arshine offer it with US DMF and CEP support. Italy hosts Procos, a European producer with FDA, EU GMP, and customer audit history. The US holds the originator business at Zoetis and the generic dosage-form makers ZyVet and Dechra. Europe hosts Dechra's Prevomax business and contract makers of veterinary tablets and injections. India offers additional API and fine chemical capacity for quinuclidinone, substituted benzaldehydes, Grignard reagents, and catalysts.

Key Maropitant Producers

Zoetis

• New Jersey-based animal health leader that sells maropitant worldwide as Cerenia tablets and injection.
• Inherited the molecule from Pfizer's animal health business, including its process patents.
• Competes on originator status, vet loyalty, broad labeling across dogs and cats, and global field sales.
• Operates under FDA Center for Veterinary Medicine and EU veterinary GMP oversight.

ZyVet Animal Health

• Pennington, New Jersey company that won the first FDA approval for generic maropitant citrate tablets.
• Sells 16, 24, 60, and 160 mg tablets referencing Cerenia.
• Competes on price, generic availability, and distribution through US veterinary channels.
• Works under FDA Center for Veterinary Medicine approval for its generic.

Dechra Pharmaceuticals

• Veterinary specialty company that markets Emeprev injection in the US and Prevomax in Europe.
• Gained FDA approval for Emeprev as the first bioequivalent maropitant injectable for dogs and cats.
• Competes on a room-temperature, benzyl alcohol-preserved formulation and a wide specialty portfolio.
• Holds US and European veterinary authorizations with GMP-certified supply.

Procos S.p.A.

• Italian API manufacturer near Novara, listed as a producer of maropitant citrate.
• Makes small-volume, high-value APIs for human and veterinary customers.
• Competes on European manufacturing, complex chemistry, and regulatory documentation.
• Holds GMP status and FDA inspection history at its Italian site.

Apino Pharma

• Chinese API manufacturer listed as a producer of maropitant citrate monohydrate.
• Supplies generic medicine manufacturers with GMP documents and certificates of analysis.
• Competes through lower Chinese production costs, multistep synthesis, and flexible batch sizes.
• Follows Chinese GMP requirements and provides documents needed by export customers.

Sichuan Qingmu Pharmaceutical

• Chinese API manufacturer based in Sichuan and listed as a producer of maropitant citrate.
• Supplies regulated markets and has FDA inspection status.
• Competes through experience in chiral synthesis, lower costs, and export capabilities.
• Follows Chinese GMP requirements and FDA requirements for exported APIs.